Cambridge Trust’s Bio-Techne TECH Stock Holding History

Cambridge Trust’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-160	Closed	-$21K	–	1147
2021 Q4	$21K	Buy	+160	New	+$19.6K	﹤0.01%	679

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return

Cambridge Trust's TECH Position: Q1 2022 in Review

Cambridge Trust sold out of Bio-Techne (TECH) in Q1 2022, closing a stake of 160 shares — an estimated $21K sold.

Cambridge Trust first reported a position in TECH in Q4 2021 and held it in 1 quarter. The position peaked at $21K in Q4 2021. 557 funds tracked by Wall St. Rank hold TECH as of Q1 2022.

Cambridge Trust reported no remaining Bio-Techne position as of Q1 2022 after selling out during the quarter.
Cambridge Trust sold 160 Bio-Techne shares in Q1 2022, an estimated $21K.
Cambridge Trust first reported a position in Bio-Techne in Q4 2021 and held it in 1 quarter.
Cambridge Trust's Bio-Techne position peaked at $21K in Q4 2021.
557 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2022.

Based on Cambridge Trust's 13F filing for Q1 2022, filed 12 May 2022.